ClinicalTrials.gg
CompletedNCT05501600NeuCLAUpdated Dec 24, 2024Results posted

Neural Correlates of Lidocaine Analgesia

A Phase 1 interventional study of Peripheral Nerve Stimulation and Lidocaine IV in Anesthesia and Pain, sponsored by Keith M Vogt. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-24.

Sponsored by Keith M Vogt · Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 204 studies testing lidocaine in Pain — 19 open to participants now, 19 under way, 1 of them phase 3. Lidocaine · Pain.

Enrollment
160th of 203
30 · median 66
Started
2022
with 5 others
Phase 1
8 of 204
none open now
Registered
169th of 204
by date

Among the 204 studies testing lidocaine in Pain, this one is the 160th largest by enrollment of the 203 interventional ones that give a count, is one of 6 that started in 2022, is one of 8 in phase 1, and was the 169th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

19 of the 204 studies testing lidocaine in Pain are open now, in 9 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About lidocaine

Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 204 studies testing lidocaine in Pain, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the effects of intravenous lidocaine on pain processing and cognitive function. Functional magnetic resonance imaging will be used to identify the neural correlates of these phenomena. The study will consist of 1 visit and involves no long-term follow up.

Read the detailed description

This is an observational cohort study of volunteer subjects, which will employ neuroimaging and behavioral measures to characterize the effects of intravenous lidocaine on pain processing and cognitive function. A steady-state effect-site concentration of lidocaine will be achieved, and a short battery of cognitive behavioral tasks will be employed. At the dose target, pain task functional MRI and resting-state connectivity will be determined. This work will use a systems neuroscience approach to fill an important knowledge gap about the central effects of intravenous lidocaine, a commonly-used opioid alternative analgesic agent.

Aim1: Determine cognitive behavioral effects of a steady-state dose of IV lidocaine using a short battery of tasks. The investigators hypothesize that the administration of lidocaine will correlate to decreased pain ratings, slowed psychomotor response, and decreased memory encoding.

Aim2: Determine the neural effects of a steady-state dose of IV lidocaine in response to acute pain, and on resting connectivity. The investigators hypothesize that pain task-related activation will decrease in the insula and anterior cingulate, corresponding to decreased ratings of pain intensity and unpleasantness. Additionally, the investigators expect widespread decreases in long-range functional connectivity between brain areas know to be involved in these two areas and other known to be involved in pain processing.

03

Conditions studied

  • Anesthesia
  • Pain

Browse trials for

Keywords

  • lidocaine
  • functional MRI
  • electric nerve stimulation
  • functional connectivity
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 70
  • Be of normal body-weight
  • Be generally healthy
  • Have none of the specific exclusion criteria
  • Have a valid email address and phone number throughout the study

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • > 40
  • Having moderate to severe sleep apnea
  • Having chronic pain requiring the regular use of pain medicine 3 or more times per week
  • Having neurologic or psychiatric disease, including benign tremor, anxiety, and depression
  • Having a history of seizures
  • Having history of cardiac rhythm disturbance (such as heart block, or atrial fibrillation)
  • Being severely claustrophobic
  • Having metal implants or non-removable metal piercings
  • Having metal-containing tattoos, particularly on the face
  • Having a history of adverse reaction to lidocaine
  • Are regularly taking: antiepileptics, antidepressants, anti-psychotics, anti-anxiety medication, stimulants, sleep-aids, or pain medication
  • Are taking prescribed medications for psychiatric or neurological conditions
  • Having to lidocaine or to any other local anesthetics of the amide type
  • Having Wolff-Parkinson-White syndrome
  • Having known renal or hepatic dysfunction
  • having glucose-6-phosphate dehydrogenase deficiency or history of methemoglobinemia
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Lidocaine

    Subjects will receive lidocaine during the drug portion of the experiment.

    Device: Peripheral Nerve Stimulation · Drug: Lidocaine IV

Interventions

  • DevicePeripheral Nerve Stimulation

    Experimental acute pain stimulus will be delivered using an electric nerve stimulator.

    Also known as: Electric Nerve Stimulation

  • DrugLidocaineStudies of LidocaineLidocaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will receive an intravenous infusion of lidocaine for about 30 minutes.

    Also known as: Xylocaine

06

What researchers measure

Primary outcomes

  1. Brain Activation to Painful Stimulation Difference: Drug-free Condition Minus Lidocaine Condition

    The Z-score is calculated by linear regression of the task timing against the MRI signal time-course (MRI data is in arbitrary units with no maximum or minimum) at each voxel (single data point in brain). Primary outcome is listed for the Right insula, but similar scores are calculated throughout the brain. Z-score of 0 indicates no task-related changes. Z-scores further from zero indicate stronger correlation between functional MRI signal change and the task timing, with positive values indicating increases in fMRI signal and negative Z-scores indicating decreases. Practically, higher positive Z-scores indicate increased brain activity and larger negative Z-scores indicate decreased brain activity. This outcome is reported as a number, as it is calculated using all the data across subjects combined into one statistical measure for the overall strength of difference in MRI signal change between two groups of data. Dispersion measures cannot be calculated for the summary Z-score.

    Time frame: 4.5 minutes

  2. Resting-state Functional Connectivity Difference: Drug-free Minus Lidocaine

    Functional connectivity (FC) measures the correlation of MRI signal time-series between brain regions. Changes in FC reflect differences in brain state, in this case between drug-free and lidocaine conditions. The reported value is the FC change between the right insula and anterior cingulate. A T-statistic of 0 indicates no change; more positive scores mean stronger connectivity in the drug-free condition, and more negative scores mean stronger connectivity with lidocaine. This outcome is a number reflecting the overall magnitude of difference between two datasets, calculated in one summary statistic. Dispersion measures cannot be calculated for the T-statistic in this analysis framework.

    Time frame: 8 minutes

Secondary outcomes

  1. Pain Intensity Score Difference, Drug-free Condition Minus Lidocaine Condition

    Numerical rating scale (0-10) pain score difference, comparing drug-free to the steady-state dose of lidocaine. Higher pain scores indicate more pain; a positive difference between pain score during the drug-free condition minus the value during the lidocaine condition indicates pain reduction (a better outcome).

    Time frame: 12 minutes

  2. Memory Performance Difference, Drug-free Minus Lidocaine Condition

    Performance on a short computer-based test of memory for visual pictures will be quantified using signal detection metric d-prime, reflecting ability (in standard deviation units) to detect previously-seen images from the background "noise" of previously un-seen images. Differences will be determined between the drug-free condition and the lidocaine condition. Higher values of d-prime indicate stronger memory performance; a positive difference for drug-free minus lidocaine condition would indicate the expected decrease in memory performance.

    Time frame: 3 minutes

  3. Motor Response Time Differences

    Response times (in ms) after hearing a tone will be recorded and compared between the drug-free and Lidocaine condition, with the calculated difference in response times reported. Higher values will reflect slower responses, which are expected under the lidocaine condition.

    Time frame: 1 minute

07

Results

Posted Dec 24, 2024

Participant flow

Participant flow — Overall Study
MilestoneLidocaine
Started30
Completed27
Not completed3

Outcome measures

PrimaryBrain Activation to Painful Stimulation Difference: Drug-free Condition Minus Lidocaine Condition

The Z-score is calculated by linear regression of the task timing against the MRI signal time-course (MRI data is in arbitrary units with no maximum or minimum) at each voxel (single data point in brain). Primary outcome is listed for the Right insula, but similar scores are calculated throughout the brain. Z-score of 0 indicates no task-related changes. Z-scores further from zero indicate stronger correlation between functional MRI signal change and the task timing, with positive values indicating increases in fMRI signal and negative Z-scores indicating decreases. Practically, higher positive Z-scores indicate increased brain activity and larger negative Z-scores indicate decreased brain activity. This outcome is reported as a number, as it is calculated using all the data across subjects combined into one statistical measure for the overall strength of difference in MRI signal change between two groups of data. Dispersion measures cannot be calculated for the summary Z-score.

Time frame:
4.5 minutes
Reported as:
Number · Z-score
Brain Activation to Painful Stimulation Difference: Drug-free Condition Minus Lidocaine Condition
Z-scoreLidocaine
Brain Activation to Painful Stimulation Difference: Drug-free Condition Minus Lidocaine Condition3.6
Statistical analysis
  • Lidocaine · Regression, Linear · p = 0.004
PrimaryResting-state Functional Connectivity Difference: Drug-free Minus Lidocaine

Functional connectivity (FC) measures the correlation of MRI signal time-series between brain regions. Changes in FC reflect differences in brain state, in this case between drug-free and lidocaine conditions. The reported value is the FC change between the right insula and anterior cingulate. A T-statistic of 0 indicates no change; more positive scores mean stronger connectivity in the drug-free condition, and more negative scores mean stronger connectivity with lidocaine. This outcome is a number reflecting the overall magnitude of difference between two datasets, calculated in one summary statistic. Dispersion measures cannot be calculated for the T-statistic in this analysis framework.

Time frame:
8 minutes
Reported as:
Number · T-statistic
Resting-state Functional Connectivity Difference: Drug-free Minus Lidocaine
T-statisticLidocaine
Resting-state Functional Connectivity Difference: Drug-free Minus Lidocaine3.25
Statistical analysis
  • Lidocaine · t-test, 2 sided · p = 0.081616
SecondaryPain Intensity Score Difference, Drug-free Condition Minus Lidocaine Condition

Numerical rating scale (0-10) pain score difference, comparing drug-free to the steady-state dose of lidocaine. Higher pain scores indicate more pain; a positive difference between pain score during the drug-free condition minus the value during the lidocaine condition indicates pain reduction (a better outcome).

Time frame:
12 minutes
Reported as:
Mean · units on a scale
Pain Intensity Score Difference, Drug-free Condition Minus Lidocaine Condition
units on a scaleLidocaine
Pain Intensity Score Difference, Drug-free Condition Minus Lidocaine Condition0.4 ± 0.2
SecondaryMemory Performance Difference, Drug-free Minus Lidocaine Condition

Performance on a short computer-based test of memory for visual pictures will be quantified using signal detection metric d-prime, reflecting ability (in standard deviation units) to detect previously-seen images from the background "noise" of previously un-seen images. Differences will be determined between the drug-free condition and the lidocaine condition. Higher values of d-prime indicate stronger memory performance; a positive difference for drug-free minus lidocaine condition would indicate the expected decrease in memory performance.

Time frame:
3 minutes
Reported as:
Mean · d-prime
Memory Performance Difference, Drug-free Minus Lidocaine Condition
d-primeLidocaine
Memory Performance Difference, Drug-free Minus Lidocaine Condition0.48 (0.12 to 0.85)
SecondaryMotor Response Time Differences

Response times (in ms) after hearing a tone will be recorded and compared between the drug-free and Lidocaine condition, with the calculated difference in response times reported. Higher values will reflect slower responses, which are expected under the lidocaine condition.

Time frame:
1 minute
Reported as:
Mean · milliseconds
Motor Response Time Differences
millisecondsLidocaine
Motor Response Time Differences10 ± 100

Adverse events

Collected over 1 hour. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lidocaine0/27 (0%)0/27 (0%)0/27 (0%)

Baseline characteristics

Completed participants

Age, Continuous
Age, Continuous(years)Lidocaine
Mean31.4 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Lidocaine
Female14
Male13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lidocaine
Hispanic or Latino1
Not Hispanic or Latino20
Unknown or Not Reported6
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lidocaine
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American3
White14
More than one race1
Unknown or Not Reported6
08

Study locations

1 site
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Nov 2023, 11 months.

Results were first posted in Dec 2024, 1 year 1 month after primary completion.

Of 118 non-industry phase 1 interventional studies under Pain, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 11 months is below that.

Counting every sponsor, half of 222 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2022
First posted
Aug 15, 2022
StartActual
Nov 22, 2022
Primary completionActual
Nov 17, 2023
CompletionActual
Nov 17, 2023
Results first posted
Dec 24, 2024
Last update
Dec 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05501600
Lead sponsor
Keith M Vogt
Responsible party
Keith M Vogt (Associate Professor of Anesthesiology & Perioperative Medicine, University of Pittsburgh) — Sponsor-investigator
First posted
Aug 15, 2022
Start date
Nov 22, 2022
Primary completion
Nov 17, 2023
Completion
Nov 17, 2023
Results posted
Dec 24, 2024
Last update
Dec 24, 2024

Study contacts

Keith M Vogt, MD, PhD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion